Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 901–1,000 of 1,018
Arias-Loza, P.-A., Hu, K., Dienesch, C., Mehlich, A. M., König, S., Jazbutyte, V., Neyses, L., Hegele‐Hartung, C., Fritzemeier, K. H., & Pelzer, T. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.084798 · Cited by 65
Rapid effects of aldosterone on clonal human vascular smooth muscle cells
Gros, R., Ding, Q., Armstrong, S., O’Neil, C. H., Pickering, J. G., & Feldman, R. D. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00407.2006 · Cited by 65
Mineralocorticoids in the Heart and Vasculature: New Insights for Old Hormones
Lother, A., Moser, M., Bode, C., Feldman, R. D., & Hein, L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124302 · Cited by 62
Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling
Takemoto, Y., Ramírez, R. J., Kaur, K., Salvador, O., Ponce‐Balbuena, D., Ramos‐Mondragón, R., Ennis, S. R., Guerrero‐Serna, G., Berenfeld, O., & Jalife, J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.014 · Cited by 67
Yoshida, M., Ma, J., Tomita, T., Morikawa, N., Tanaka, N., Masamura, K., Kawai, Y., & Miyamori, I. (2005) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2005.03722.x · Cited by 65
Structural and molecular determinants of mineralocorticoid receptor signalling
Großmann, C., Almeida‐Prieto, B., Nolze, A., & de la Rosa, D. Á. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15746 · Cited by 66
Savarese, G., Lindberg, F., Filippatos, G. S., Butler, J., & Anker, S. D. (2023) · Diabetologia · doi:10.1007/s00125-023-06031-1 · Cited by 68
Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics
Roumen, L., Sanders, M. P. A., Pieterse, K., Hilbers, P. A. J., Plate, R., Custers, E. M. G., de Gooyer, M. E., Smits, J. F. M., Beugels, I. P. E., Emmen, J. M. A., et al. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9128-9 · Cited by 71
Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
Yang, J., & Young, M. J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.005 · Cited by 68
Briet, M. B., Barhoumi, T., Mian, M. O. R., Coelho, S. C., Ouerd, S., Rautureau, Y., Coffman, T. M., Paradis, P., & Schiffrin, E. L. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.07074 · Cited by 70
Weir, M. R., Bakris, G. L., Gross, C., Mayo, M. R., Garza, D., Stasiv, Y., Yuan, J., Berman, L., & Williams, G. H. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.019 · Cited by 65
Li, C., Sun, X., Zeng, M., Zheng, X., Zhang, Y., Wan, Q., Zhang, W., Shi, C., Du, L., Ai, T.-J., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09070 · Cited by 64
Cooper, L. B., Lippmann, S., Greiner, M. A., Sharma, A., Kelly, J. P., Fonarow, G. C., Yancy, C. W., Heidenreich, P. A., & Hernandez, A. F. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006540 · Cited by 68
Κωνσταντίνου, Κ., Tsioufis, C. P., Koumelli, A., Mantzouranis, M., Kasiakogias, A., Doumas, M. N., & Tousoulis, D. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13622 · Cited by 76
Ortiz, A., Ferro, C. J., Balafa, O., Burnier, M., Ekart, R., Halimi, J.-M., Kreutz, R., Mark, P. B., Persu, A., Rossignol, P., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab167 · Cited by 62
Nishiyama, A., & Abe, Y. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj05003x3 · Cited by 64
Mineralocorticoid receptor activation in obesity hypertension
Nagase, M., & Fujita, T. (2009) · Hypertension Research · doi:10.1038/hr.2009.86 · Cited by 72
Stowasser, M., & Gordon, R. D. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00050-2 · Cited by 73
McMurray, J. J. V., & O’Connor, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1401231 · Cited by 68
Georgianos, P. I., & Agarwal, R. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac124 · Cited by 69
Averkov, O. V., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Nikulina, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Abugov, S. A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6319 · Cited by 77
KANOUPAKIS, E. M., Manios, E. G., Kallergis, E. M., Mavrakis, H. E., Goudis, C. A., Saloustros, I. G., Milathianaki, M. E., CHLOUVERAKIS, G. I., & Vardas, P. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.040 · Cited by 63
Adipose Tissue and Adrenal Glands: Novel Pathophysiological Mechanisms and Clinical Applications
Kargi, A. Y., & Iacobellis, G. (2014) · International Journal of Endocrinology · doi:10.1155/2014/614074 · Cited by 74
Daneault, B., Généreux, P., Kirtane, A. J., Witzenbichler, B., Guagliumi, G., Paradis, J., Fahy, M. P., Mehran, R., & Stone, G. W. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.040 · Cited by 65
Vascular-targeted therapies for Duchenne muscular dystrophy
Ennen, J. P., Verma, M., & Asakura, A. (2013) · Skeletal Muscle · doi:10.1186/2044-5040-3-9 · Cited by 74
Wang, Q., Clément, S., Gabbiani, G., Horisberger, J., Burnier, M., Rossier, B. C., & Hümmler, E. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00386.2003 · Cited by 63
Fraccarollo, D., Galuppo, P., Schmidt, I., Ertl, G., & Bauersachs, J. K. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.03.001 · Cited by 63
Heart Failure with Reduced Ejection Fraction in Women
Mentzer, G. G., & Hsich, E. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.08.003 · Cited by 71
Hu, Q., Yin, L., & Hartmann, R. W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401430e · Cited by 62
Validity of claims‐based definitions of left ventricular systolic dysfunction in Medicare patients
Li, Q., Glynn, R. J., Dreyer, N. A., Liu, J., Mogun, H., & Setoguchi, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2146 · Cited by 62
Kiyomoto, H., Rafiq, K., Mostofa, M., & Nishiyama, A. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r02cr · Cited by 65
Ori, Y., Chagnac, A., Korzets, A., Zingerman, B. V., Herman‐Edelstein, M., Bergman, M., Gafter, U., & Salman, H. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs587 · Cited by 62
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients
Drechsler, C., Ritz, E., Tomaschitz, A., Pilz, S., Schönfeld, S., Blouin, K., Bidlingmaier, M., Hammer, F., Krane, V., März, W., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs361 · Cited by 63
Favre, J., Gao, J., Zhang, A. D., Rémy‐Jouet, I., Ouvrard‐Pascaud, A., Dautréaux, B., Escoubet, B., Thuillez, C., Jaisser, F., & Richard, V. J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00552.2010 · Cited by 62
Grijalva, C. G., Biaggioni, I., Griffin, M. R., & Shibao, C. A. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006848 · Cited by 68
Boehm, M., Arnold, N. D., Braithwaite, A. T., Pickworth, J. A., Lu, C., Novoyatleva, T., Kiely, D. G., Grimminger, F., Ghofrani, H. A., Weißmann, N., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0604-x · Cited by 62
Craft, J. L. (2004) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2004.11927973 · Cited by 62
Ulmschneider, S., Müller‐Vieira, U., Mitrenga, M., Hartmann, R. W., Marchais‐Oberwinkler, S., Klein, C. D. P., Bureik, M., Bernhardt, R., Antes, I., & Lengauer, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049600p · Cited by 62
Heidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000099 · Cited by 70
Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., Boletis, J., Toto, R., Umpierrez, G. E., Wanner, C., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab336 · Cited by 61
Self-citationAdverse Effects of Aldosterone: Beyond Blood Pressure
Brown, J. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030142 · Cited by 65
Maubec, E., Laouenan, C., Deschamps, L., Nguyen, V. T., Scheer-Senyarich, I., Wackenheim-Jacobs, A.-C., Steff, M., Duhamel, S., Tubiana, S., Brahimi, N., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.44 · Cited by 63
Latouche, C., Sainte–Marie, Y., Steenman, M., Castro‐Chaves, P., Náray‐Fejes‐Tóth, A., Fejes‐Tóth, G., Farman, N., & Jaisser, F. (2010) · Endocrinology · doi:10.1210/en.2010-0237 · Cited by 61
Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology
Funder, J. W., & Mihailidou, A. S. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.029 · Cited by 66
Bouligand, J., Delemer, B., Hecart, A.-C., Meduri, G., Viengchareun, S., Amazit, L., Trabado, S., Fève, B., Guiochon-Mantel, A., Young, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013563 · Cited by 60
Gergely, R., Kovács, I., Schneider, M., Resch, M., Papp, A., Récsán, Z., Nagy, Z. Z., & Ecsedy, M. (2016) · Retina · doi:10.1097/iae.0000000000001303 · Cited by 61
initiative, F. T. H. ‘. I. A. (. I. A. T. H.-R. M. I. D., Ferreira, J. P., Girerd, N., Pellicori, P., Duarte, K., Girerd, S., Pfeffer, M. A., McMurray, J. J. V., Pitt, B., Dickstein, K., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0731-2 · Cited by 62
Self-citationMcEneaney, V., Harvey, B. J., & Thomas, W. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.03.043 · Cited by 61
Faresse, N., Ruffieux-Daidié, D., Salamin, M., Gómez-Sánchez, C. E., & Staub, O. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00285.2010 · Cited by 62
Left ventricular remodeling after myocardial infarction: past, present, and future.
Tiyyagura, S. R., & Pinney, S. (2006) · PubMed · Cited by 80
Anuka, E., Gal, M., Stocco, D. M., & Orly, J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.003 · Cited by 60
Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone
Muñoz‐Durango, N., Vecchiola, A., González-Gómez, L. M., Simón, F., Riedel, C. A., Fardella, C., & Kalergis, A. M. (2015) · BioMed Research International · doi:10.1155/2015/652738 · Cited by 68
Thum, T., Schmitter, K., Fleißner, F., Wiebking, V., Dietrich, B., Widder, J. D., Jazbutyte, V., Hahner, S., Ertl, G., & Bauersachs, J. K. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq254 · Cited by 60
Yeboah, J., Bluemke, D. A., Hundley, W. G., Rodríguez, C. J., Lima, J. A. C., & Herrington, D. M. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.09.002 · Cited by 60
Georgiopoulou, V. V., Kalogeropoulos, A. P., Giamouzis, G., Agha, S. A., Rashad, M. A., Waheed, S., Laskar, S. R., Smith, A. L., & Butler, J. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.807032 · Cited by 60
Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period.
Borrello, F., Beahan, M., Klein, L., & Gheorghiade, M. (2003) · PubMed · Cited by 65
Youn, Y. J., Yoo, B., Lee, J., Kim, J., Han, S. W., Jeon, E., Cho, M., Kim, J., Kang, S., Chae, S. C., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1093 · Cited by 64
Böhm, M., Ferreira, J. P., Mahfoud, F., Duarte, K., Pitt, B., Zannad, F., & Rossignol, P. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa132 · Cited by 59
Self-citationVecchio, L. D., Procaccio, M., Viganò, S. M., & Cusi, D. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0362 · Cited by 60
Pradhan, A. D., LaCroix, A. Z., Langer, R. D., Trevisan, M., Lewis, C. E., Hsia, J. A., Oberman, A., Kotchen, J. M., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000134965.73212.a6 · Cited by 66
Yoshida, K., Kim‐Mitsuyama, S., Wake, R., Izumiya, Y., Izumi, Y., Yukimura, T., Ueda, M., Yoshiyama, M., & Iwao, H. (2005) · Hypertension Research · doi:10.1291/hypres.28.447 · Cited by 60
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives
Epstein, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg339 · Cited by 62
Satoh, F., Ito, S., Itoh, H., Rakugi, H., Shibata, H., Ichihara, A., Omura, M., Takahashi, K., Okuda, Y., & Iijima, S. (2020) · Hypertension Research · doi:10.1038/s41440-020-00570-5 · Cited by 60
Buysse, J., Huang, I., & Pitt, B. (2011) · Future Cardiology · doi:10.2217/fca.11.71 · Cited by 61
Self-citationInteractions of the mineralocorticoid receptor – Within and without
Yang, J., & Fuller, P. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.001 · Cited by 63
Hyperkalemia in patients with heart failure: Incidence, prevalence, and management
Desai, A. S. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0037-1 · Cited by 64
Abbas, S., Ihle, P., Harder, S., & Schubert, I. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3748 · Cited by 58
Bhardwaj, A., Rehman, S., Mohammed, A. A., Baggish, A. L., Moore, S. A., & Januzzi, J. L. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.01.005 · Cited by 59
de Denus, S., Tardif, J., White, M., Bourassa, M. G., Racine, N., Lévesque, S., & Ducharme, A. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.030 · Cited by 64
CSI position statement on management of heart failure in India
Guha, S., Harikrishnan, S., Ray, S., Sethi, R., Ramakrishnan, S., Banerjee, S., Bahl, V. K., Goswami, K. C., Banerjee, A. K., Shanmugasundaram, S., et al. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.05.003 · Cited by 65
Heart Failure in the Oldest Patients: The Impact of Comorbid Conditions
Rich, M. W. (2005) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2005.03890.x · Cited by 59
Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based Study
Ko, D. T., Juurlink, D. N., Mamdani, M., You, J. J., Wang, J. T., Donovan, L. R., & Tu, J. V. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.01.003 · Cited by 60
Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study
Parikh, N. I., Gona, P. N., Larson, M. G., Wang, T. J., Newton‐Cheh, C., Levy, D. A., Benjamin, E. J., Kannel, W. B., & Vasan, R. S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm399 · Cited by 59
Kintscher, U., & Edelmann, F. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01899-0 · Cited by 62
The spectrum of post-myocardial infarction care: From acute ischemia to heart failure
Akhtar, K. H., Khan, M. S., Baron, S. J., Zieroth, S. R., Estep, J. D., Burkhoff, D., Butler, J., & Fudim, M. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.017 · Cited by 60
Pathogenesis of aortic stenosis: not just a matter of wear and tear.
Sverdlov, A. L., Ngo, D. T. M., Chapman, M., Ali, O. A., Chirkov, Y. Y., & Horowitz, J. D. (2011) · Europe PMC (PubMed Central) · Cited by 89
Protective Effect of Spironolactone on Endothelial Cell Apoptosis
Williams, T. A., Verhovez, A., Milan, A., Veglio, F., & Mulatero, P. (2006) · Endocrinology · doi:10.1210/en.2005-1318 · Cited by 58
Akizuki, O., Inayoshi, A., Kitayama, T., Yao, K., Shirakura, S., Sasaki, K., Kusaka, H., & Matsubara, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.001 · Cited by 58
Feraco, A., Armani, A., Mammi, C., Fabbri, A., Rosano, G. M. C., & Caprio, M. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.02.012 · Cited by 60
Aldosterone Dysregulation With Aging Predicts Renal Vascular Function and Cardiovascular Risk
Brown, J. M., Underwood, P. C., Ferri, C., Hopkins, P. N., Williams, G. H., Adler, G. K., & Vaidya, A. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03231 · Cited by 57
Ménard, J., Rigel, D. F., Watson, C. E., Jeng, A. Y., Fu, F., Beil, M. E., Liu, J., Chen, W., Hu, C.-W., Leung-Chu, J., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0340-9 · Cited by 61
Butler, J., Ezekowitz, J. A., Collins, S. P., Givertz, M. M., Teerlink, J. R., Walsh, M. N., Albert, N. M., Canary, C. A. W., Carson, P. E., Colvin, M. M., et al. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.02.005 · Cited by 63
Impact of Adrenal Steroids on Regulation of Adipose Tissue
Infante, M., Armani, A., Mammi, C., Fabbri, A., & Caprio, M. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160037 · Cited by 60
Pitt, B., Bushinsky, D. A., Kitzman, D. W., Ruschitzka, F. T., Metra, M., Filippatos, G. S., Rossignol, P., Mond, C. D., Garza, D., Berman, L., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12265 · Cited by 58
Self-citationThe Role of Mineralocorticoid Receptor Expression in Brain Remodeling after Cerebral Ischemia
Oyamada, N., Sone, M., Miyashita, K., Park, K., Taura, D., Inuzuka, M., Sonoyama, T., Tsujimoto, H., Fukunaga, Y., Tamura, N., et al. (2008) · Endocrinology · doi:10.1210/en.2007-1770 · Cited by 58
Pitt, B., Stier, C. T., & Rajagopalan, S. (2003) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2003.025 · Cited by 58
Self-citationMineralocorticoid Receptor Activation and Oxidative Stress
Funder, J. W. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.098012 · Cited by 55
VersorgungsLeitlinie, N. (2011) · Cited by 58
Mineralocorticoid receptor in cardiovascular diseases—Clinical trials and mechanistic insights
Bauersachs, J. K., & López‐Andrés, N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15708 · Cited by 62
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials
Oraii, A., Healey, J. S., Kowalik, K., Pandey, A. K., Benz, A. P., Wong, J. A., Conen, D., & McIntyre, W. F. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad811 · Cited by 58
Aldosterone receptor antagonists: current perspectives and therapies
Clark, D., Guichard, J. L., Calhoun, & Ahmed (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33759 · Cited by 66
Ersbøll, M. K., Valeur, N., Mogensen, U. M., Andersen, M. J., Møller, J. E., Hassager, C., Søgaard, P., & Køber, L. (2012) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2012.09.006 · Cited by 57
von Scheidt, W., Zugck, C., Pauschinger, M., Hambrecht, R., Bruder, O., Hartmann, A., Rauchhaus, M., Zahn, R., Brachmann, J., Tebbe, U., et al. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0743-x · Cited by 58
Structural determinants of ligand binding to the mineralocorticoid receptor
Huyet, J., Pinon, G. M., Fay, M., Rafestin-Oblin, M. E., & Fagart, J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.035 · Cited by 63
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure
Borgdorff, M. A. J., Bartelds, B., Dickinson, M. G., Paul Steendijk, A., & Berger, R. M. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.102 · Cited by 57
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure
Sica, D. A. (2015) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-11-4-235 · Cited by 60
Ferreira, J. P., Girerd, N., Duarte, K., Coiro, S., McMurray, J. J. V., Dargie, H. J., Pitt, B., Dickstein, K., Testani, J. M., Zannad, F. M., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003500 · Cited by 61
Self-citationPathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy
Alonso, N., Moliner, P., & Mauricio, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_105 · Cited by 59
Li, Y., Wang, Y.-C., Wang, Y., Liu, J., Lee, C., Chen, C., Hsieh, C., Kuo, F. Y., Huang, W., Sung, S., et al. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.06.002 · Cited by 59
Aldosterone target organ protection by eplerenone
Rudolph, A. E., Rocha, R., & McMahon, E. G. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.047 · Cited by 58
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.